Analyst Price Targets — DARE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 24, 2024 7:45 am | Douglas Tsao | H.C. Wainwright | $12.00 | $3.50 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Dare Bioscience (DARE) |
Latest News for DARE
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of its "Across the U.S." Virtual Bus Tour Webinar Series, a multi-event investor engagement initiative designed to provide shareholders with direct access to the…
Live video webcast on Tuesday, July 14 th , at 4:00 PM ET Register here
Live video webcast on Tuesday, July 14th, at 4:00 PM ETRegister here SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will participate in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET.
Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DARE.
U.S. House Trading
No House trades found for DARE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.